Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL28409020 | 0.92 | FFAR3 (0.48) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Biphenyl SCHEMBL460021 | 0.86 | SMN1; SMN2 (0.64) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL585470 | 0.84 | FFAR3 (0.50) | FFAR3PTGER1PTGER4PTGER3PTGER2 | |
| Butyric Acid SCHEMBL7069607 | 0.81 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Resorcinol SCHEMBL8461221 | 0.81 | FFAR3 (0.54) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7892456 | 0.81 | TSHR (0.58) | PTGER1PTGER4PTGER3PTGER2SMN1; SMN2 | |
| Butyric Acid SCHEMBL29482175 | 0.81 | FFAR3 (0.54) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL11626727 | 0.81 | FFAR3 (0.87) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL11626724 | 0.81 | FFAR3 (0.87) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1994703 | 0.81 | FFAR3 (0.87) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104995248-B | Rubber composition comprising metal carboxylate and method for preparing same | 株式会社普利司通 | 2017-12-08 | — | — | CN | claimed |
| CN-104995248-B | Rubber composition comprising metal carboxylate and method for preparing same | 株式会社普利司通 | 2017-12-08 | — | — | CN | disclosed |
| CN-103619831-B | Azole heterocyclic compound, its preparation method, pharmaceutical composition and purposes | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-05-04 | — | — | CN | disclosed |
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| CN-101541725-B | Method for producing carbonyl compound an pro-oxidant used for production of carbonyl compound | UNIV NAGOYA NAT UNIV CORP | 2013-08-28 | — | — | CN | disclosed |
| US-8394995-B2 | Process for preparation of carbonyl compound and pro-oxidant for preparation of carbonyl compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-2085373-B1 | METHOD FOR PRODUCING CARBONYL COMPOUND AN PRO-OXIDANT USED FOR PRODUCTION OF CARBONYL COMPOUND | UNIV NAGOYA NAT UNIV CORP (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100041917-A1 | PROCESS FOR PREPARATION OF CARBONYL COMPOUND AND PRO-OXIDANT FOR PREPARATION OF CARBONYL COMPOUND | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2085373-A1 | METHOD FOR PRODUCING CARBONYL COMPOUND AN PRO-OXIDANT USED FOR PRODUCTION OF CARBONYL COMPOUND | National University Corporation Nagoya University (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| CN-1906143-A | Method of deuteration using mixed catalyst | WAKO PURE CHEM IND LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1707548-A1 | METHOD OF DEUTERATION USING MIXED CATALYST | Wako Pure Chemical Industries, Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| CN-1826325-A | 4,5-dihydro-imidazole as P2X7 ion channel blockers | AVENTIS PHARMA INC (US) | 2006-08-30 | — | — | CN | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | HDHD5, DHX35, HRH3 | FFAR3 3968/4885HDAC3 673/4885HDAC1 438/4885 |
| US-20100041917-A1 | PROCESS FOR PREPARATION OF CARBONYL COMPOUND AND PRO-OXIDANT FOR PREPARATION OF CARBONYL COMPOUND | CBR1, CBR3, NOX4 | FFAR3 2152/4885HDAC3 1292/4885HDAC1 537/4885 |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | FFAR3 417/4885HDAC3 1673/4885HDAC1 2615/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | FFAR3 417/4885HDAC3 1673/4885HDAC1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.